Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Plain-language summary
This trial is testing duvelisib (an oral PI3K inhibitor) for patients with angioimmunoblastic T-cell lymphoma (AITL) or TFH lymphomas or peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) who have been newly diagnosed and have not yet received treatment as well as those who have responded to prior therapy and may receive maintenance treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Biospecimen Collection (PROCEDURE): Undergo blood sample collection | Bone Marrow Aspiration (PROCEDURE): Undergo bone marrow aspiration | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow biopsy | Computed Tomography (PROCEDURE): Undergo CT scan | Duvelisib (DRUG): Given PO | Positron Emission Tomography (PROCEDURE): Undergo PET scan | Survey Administration (OTHER): Ancillary studies
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Duvelisib, Positron Emission Tomography, Survey Administration
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details